PILAR ARABIA: Open Payments
NPI 1669665097 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,916 in 89 payments from 13 companies in 2025. Trend: 2023 $767 · 2024 $482 · 2025 $1,916
Food & beverage: $1,916
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 25 | $371 |
| Janssen Pharmaceuticals, Inc | 9 | $340 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $263 |
| Alkermes, Inc. | 8 | $224 |
| E.R. Squibb & Sons, L.L.C. | 13 | $193 |
| ABBVIE INC. | 5 | $186 |
| Neurocrine BioSciences, Inc. | 7 | $162 |
| ACADIA Pharmaceuticals Inc | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Eisai Inc. | 1 | $29 |
Products named: REXULTI, CAPLYTA, ARISTADA, SPRAVATO, COBENFY, INGREZZA, VRAYLAR, INVEGA SUSTENNA.
Industry payments across NV — which companies pay providers there.
